Arrowhead announced that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dose-escalating study to evaluate single and multiple ascending doses of ARO-DM1, the company’s investigational RNA interference therapeutic, in up to 48 subjects with type 1 myotonic dystrophy. DM1 is the most common adult-onset muscular dystrophy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARWR:
